Introduction

Hepatocellular carcinoma (HCC) is the commonest primary malignant tumor of hepatocytes, the fifth frequent cancer and the third leading cause of cancer-related mortality globally, after lung cancer and stomach cancer [1]. HCC may be frequently diagnosed and it is the leading cause of cancer-related mortality globally, after lung cancer. Hepatocellular carcinoma (HCC) is the commonest primary malignancy of the liver, while its overexpressed gene targets are primarily related to aberrant cell proliferation which participates in nucleotide metabolism, DNA replication, and transcription [11]. Another study has demonstrated that the hepatitis B virus-related estrogen receptor alpha is modulated by miR-130a in HepG2.2.15 human HCC cells [12]. Early growth response 1 (EGR1) pertains to the EGR family of C2H2-type zinc-finger proteins, which is a transcriptional modulator and controls many target genes participated in cell proliferation, differentiation, and survival [13]. A study has shown that EGR1 is targeted by miR-130a. With the increase of dexmedetomidine concentration, HCCLM3 cell viability was correspondingly inhibited, miR-130a expression was elevated and EGR1 expression was decreased. Dexmedetomidine, upregulating miR-130a or downregulating EGR1 inhibited proliferation, invasion, and migration, and promoted apoptosis of HCCLM3 cells. MiR-130a upregulation/downregulation enhanced/impaired the effect of dexmedetomidine on cell biological behaviors. Our study provides evidence that raising miR-130a enhances the inhibitory effects of dexmedetomidine on HCC cellular growth via inhibiting EGR1. Thus, miR-130a may be a potential candidate for the treatment of HCC.

Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis

Lei Zhou1, Juanni Li2, Xing Liu1, Yongzhong Tang1, Tunliang Li1, Huiyin Deng1, Jia Chen1, Xinlin Yin3,4, Kuan Hu5 and Wen Ouyang1,5,6

© The Author(s) 2022

Accumulating evidence has revealed the role of microRNAs (miRs) in hepatocellular carcinoma (HCC). Dexmedetomidine, a highly selective α2-adrenergic agonist, is widely used in perioperative settings for analgesia and sedation. Herein, we aimed to determine whether dexmedetomidine might directly regulate miR-130a/early growth response 1 (EGR1) axis in HCC and explore the related mechanisms. miR-130a and EGR1 expression were determined in HCC tissues and their correlation was evaluated. Human HCC cell line HCCLM3 was selected. Upon the determination of the optimal concentration of dexmedetomidine, HCCLM3 cells were treated with dexmedetomidine, miR-130a- or EGR1-related oligonucleotides or plasmids were transfected into cells to explore their functions in cell biological behaviors. miR-130a and EGR1 levels in cells were tested. The targeting relationship between miR-130a and EGR1 was verified. miR-130a was inhibited while EGR1 was elevated in HCC tissues and they were negatively correlated. EGR1 was targeted by miR-130a. With the increase of dexmedetomidine concentration, HCCLM3 cell viability was correspondingly inhibited, miR-130a expression was elevated and EGR1 expression was decreased. Dexmedetomidine, upregulating miR-130a or downregulating EGR1 inhibited proliferation, invasion, and migration, and promoted apoptosis of HCCLM3 cells. MiR-130a upregulation/downregulation enhanced/impaired the effect of dexmedetomidine on cell biological behaviors. Our study provides evidence that raising miR-130a enhances the inhibitory effects of dexmedetomidine on HCC cellular growth via inhibiting EGR1. Thus, miR-130a may be a potential candidate for the treatment of HCC.

Cell Death Discovery (2022) 8:31 ; https://doi.org/10.1038/s41420-021-00805-5
suggested that EGR1 plays an antitumor role by downregulating the transcriptional level of CD24A, a functional liver tumor-initiating cell marker, in HCC [14]. Another study has revealed that EGR1 enhances hypoxia-induced autophagy to raise chemoresistance of HCC cells [15]. At present, there is no research on the target relationship between miR-130a and EGR1 in HCC. Thus, in this study, the function and mechanism of DEX and miR-130a/EGR1 axis in HCC cells were investigated.

**RESULTS**

miR-130a is downregulated and EGR1 is upregulated in HCC; miR-130a targets EGR1

First, miR-130a in HCC tissues and adjacent normal tissues was tested by RT-qPCR. In HCC tissues, miR-130a expression was downregulated (Fig. 1A). The relationship between miR-130a expression and clinicopathological characteristics of HCC patients was evaluated. All patients were divided into miR-130a high expression group and miR-130a low expression group using the median level of miR-130a as the cutoff value. The findings implied that miR-130a expression levels were correlated with tumor size ($P = 0.014$), TNM stage ($P = 0.019$), and tumor differentiation ($P = 0.024$) (Table 1). Additionally, patients with low expression of miR-130a had poorer overall survival (Fig. 1B). A summary table (Table 2) detailed the expression of miR-130a in tumor and adjacent normal tissues. miR-130a expression was also detected in HCC cell lines. It was manifested that miR-130a was downregulated in HCC cell lines (Huh7, Hep3B, MHCC97H, and HCCLM3) (Fig. 1C). HCCLM3 cells were selected for subsequent experiments.

The target prediction tools, including miRanda, starBase, and DIANA, were applied to identify potential targets of miR-130a. Then, EGR1 (Fig. 1D) was picked because of its relation to HCC progression [16–18]. To further test whether EGR1 was a direct target of miR-130a, EGR1 3’-UTR-WT, and 3’UTR-MUT were cloned to psi-CHECK2. Then, the results demonstrated that miR-130a mimic reduced the luciferase activity of EGR1 3’-UTR-WT in HCCLM3 cells (Fig. 1E) but not affect that of EGR1 3’-UTR-MUT.

EGR1 expression in HCC tissues and adjacent normal tissues was tested by RT-qPCR and immunohistochemistry. In HCC tissues, EGR1 expression was upregulated (Fig. 1F, G). Moreover, The Pearson correlation analysis revealed a remarkably negative correlation between the expression of miR-130a and EGR1 in HCC tissues ($r = -0.717$, $P < 0.001$, Fig. 1H). EGR1 expression was also detected in HCC cell lines. It was manifested that EGR1 was upregulated in HCC cell lines (Huh7, Hep3B, MHCC97H, and HCCLM3) (Fig. 1I, J). The results confirmed that the dysregulation of miR-130a/EGR1 axis may be involved in the occurrence and development of HCC.

DEX suppresses the viability of HCCLM3 cells

Trypan blue staining revealed that (Fig. 2A) DEX of 1 nmol/L had no effect on the viability of HCCLM3 cells, while DEX of 10 nmol/L was manifested that miR-130a was downregulated in HCC cell lines (Huh7, Hep3B, MHCC97H, and HCCLM3) (Fig. 1C). HCCLM3 cells were selected for subsequent experiments.

**Fig. 1** HCC tissues and cells show reduced miR-130a and elevated EGR1; miR-130a targets EGR1. A, miR-130a expression in HCC tissues and adjacent normal tissues detected by RT-qPCR ($n = 83$); B, The prognostic value of miR-130a in HCC patients; C, miR-130a expression in HCC cells detected by RT-qPCR ($n = 3$); D, Predicted binding sites of miR-130a and EGR1 3’-UTR, and mutant sites of EGR1 3’-UTR in EGR-WT reporter; E, The targeting relation between miR-130a and EGR1 verified by dual-luciferase reporter gene assay; F, EGR1 expression in HCC tissues and adjacent normal tissues detected by RT-qPCR ($n = 83$); G, EGR1 expression in HCC tissues and adjacent normal tissues detected by immunohistochemistry (scale bar = 50 μm; $n = 83$); H, Correlation between EGR1 and miR-130a expression in HCC tissues detected by Pearson test ($n = 83$); I, J, EGR1 expression in normal hepatocytes and HCC cells detected by RT-qPCR and western blot analysis ($N = 3$); The data were expressed as mean ± standard deviation and compared by t-test or one-way ANOVA.
Therefore, a conclusion was drawn that DEX or upregulated miR-130a suppressed the growth of HCC cells.

### Silencing EGR1 inhibits HCC progression

EGR1 is a transcription factor involved in the regulation of cell proliferation and apoptosis, and it is evident that EGR1 promotes the development of prostate cancer [19]. To explore EGR1’s effects in HCC, HCC cells were transfected with oe-EGR1 and si-EGR1. RT-qPCR and western blot analysis detection displayed that (Fig. 4A, B) oe-EGR1 elevated but si-EGR1 reduced EGR1 expression level in HCC cells.

Then, cellular experiments further explored that in HCC cells overexpressing EGR1, the malignant phenotypes were promoted while in those depleting EGR1, cell growth was inhibited (Fig. 4C-G). The outcomes indicated that depletion of EGR1 inhibited the biological activities of HCC cells.

### Elevating miR-130a enhances the inhibitory effects of DEX on HCC

To further clarify the relationship between DEX, miR-130a, and HCC, we treated HCC cells with DEX and transfected with miR-130a mimic/inhibitor. Then, it was measured by RT-qPCR that transfection of miR-130a mimic elevated but that of miR-130a inhibitor reduced miR-130a expression in DEX-treated HCC cells (Fig. 5A). Also, it was observed that elevating miR-130a further suppressed the malignant progression of DEX-treated HCC cells. On the contrary, knocking down miR-130a had the opposite functions on DEX-treated HCC cells (Fig. 5B-F). It was informed that DEX mediated miR-130a/EGR1 axis in HCC process.

### DISCUSSION

HCC is a highly invasive malignant tumor with a poor prognosis [20]. In this work, we have identified that DEX or miR-130a overexpression can inhibit the proliferation, invasion and migration, promoted apoptosis of HCC cells while miR-130a inhibition functions with the opposite effects. In addition, we discovered that miR-130a upregulation enhanced DEX-induced inhibitory effects on HCC cell progression while miR-130a inhibition reversed those effects on HCC. Shortly, we have delineated that DEX upregulated miR-130a to suppress EGR1 expression, thereby impeding HCC cell progression (Fig. 6).

Unlike opioids and other commonly used sedatives (such as propofol, fentanyl, and midazolam), DEX works out sedative effects without causing respiratory depression [21]. DEX allows patients to breathe spontaneously during sedation, thereby reducing the risk of respiratory depression [22]. Except for the sedative effects, DEX also exhibits antitumor effects just like morphine [23], propofol [24], midazolam [25], diazepam [26], sufentanil [27], tramadol [28], and many other classic sedative and analgesic drugs. To explore the performance of DEX in HCC, we performed in vitro experiments, and eventually unveiled that DEX suppressed HCC cell development. A study has shown that DEX blocks cell proliferation, migration, and invasion and accelerates cell apoptosis in ovarian cancer [29], while another study has implied that DEX inhibits osteosarcoma cell proliferation and migration, and promotes apoptosis by regulating miR-520a-3p [30]. As for the role of DEX in HCC, a study has indicated that cell apoptosis in liver tissues is reduced after DEX treatment [31]. Another study has revealed that DEX downregulates cleavage of caspase-3, thus suppressing apoptosis of hepatocytes [32]. Furthermore, evidence has shown that DEX could attenuate the proliferation of liver cells [33]. However, it is previously discovered that DEX accelerates metastasis of breast, lung, and colon cancers [34]. Adversely, DEX is able to stimulate tumour metastasis after lung cancer surgery [35]. Therefore, the promoting or inhibitory functions of DEX in tumor progression vary in different situations.
Emerging evidence has shown that miRNAs play an essential role in tumorigenesis, acting as oncogenes or tumor suppressors [36]. miR-130a is regarded as a tumor suppressor gene in many human tumors, and its overexpression can effectively inhibit the proliferation and invasion of tumor cells and induce apoptosis [37–39]. To identify whether miR-130a owns the antitumor effect in HCC, we implemented various experiments and finally confirmed that miR-130a overexpression hindered HCC progression. Echoed with our finding [40], miR-130a expression is recently reported to decline, which is correlated with the poor prognosis of HCC patients [41, 42]. In fact, a study has shown that miR-130a attenuates HCV replication through upregulating the innate immune response when HCV infection is the main cause of chronic hepatitis and HCC [43]. It has been suggested that restoration of miR-130a-3p attenuates the cell migration and invasiveness in gemcitabine-resistant HCC cells [40]. It is reported that overexpressed miR-130a resists cisplatin-induced suppression of HCC cell proliferation [44]. Collectively, miR-130a functioned to depress the progression of HCC.

miRNA regulates the target genes in tumors [45]. In this study, we clarified that miR-130a targeted EGR1, which enhanced the aggressiveness of HCC cells. It is customarily considered that EGR1 activates hepatocyte growth factor (HGF)-induced cell invasion in HCC cells and heparin suppresses HGF-induced cellular invasion through the depletion of EGR1 [46]. Also, it is reported that EGR1 expression is markedly heightened in HCC tissues and repressing EGR1 partially suppresses the proliferation of HCC cells [47, 48]. EGR1 overexpression restores the anti-proliferative and migratory properties of HCC cells while EGR1 downregulation owns the opposite functions [49]. There is a study implying that EGR1 induces lncRNA FOXD2-AS1 to upregulate, thereby accelerating HCC progression [50]. Moreover, suppressing EGR1 is documented to impair malignant phenotypes of HCC [51]. Anyway, downregulating EGR1 could delay HCC progression which is consistent with previous researches.

CONCLUSION

In conclusion, our findings identify that DEX can suppress the proliferation and facilitate apoptosis of HCC cells via upregulating miR-130a and inhibiting EGR1 expression, thus offering a new target for the treatment of HCC. However, the trial size in the designed experiment was relatively small, therefore, the collected results need further verification in a larger cohort. In the future study, the relative pathways and downstream pathways involved in miR-130a/EGR1 axis regulating HCC shall be extensively explored. Starting from other studies which have been demonstrated that EGR1 suppresses the PI3K/AKT pathway, in the present study the hypothesis is that the axis DEX/miR-130a/EGR1 may also regulate the PI3K/AKT signaling pathway, participating in the proliferation and apoptosis of HCC cells. The hypothesis needs further studies in the future.

METHODS

Compliance with ethical standards

All animal experiments were in tally with the Guide for the Care and Use of Laboratory Animal of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of The Third Xiangya Hospital, Central South University. All patients signed an informed consent form. The clinical sample collection program was approved by the ethics committee of the Third Xiangya Hospital, and the approval number is “KY2019–125”.

Specimen collection

Clinical HCC tissue specimens (n = 83) and adjacent normal tissues (≥ 3 cm from the cancer tissues) were resected by general surgery from HCC patients (63 males and 20 females) who were confirmed by pathology in the The Third Xiangya Hospital, Central South University. The specimens were divided into 2 parts: 1 part was immediately placed in liquid nitrogen for later use; the other part was fixed with 4% formaldehyde and paraffin-embedded for routine histological staining.

Cell culture

Human HCC cell lines Huh7, Hep3B, MHCC97H, and HCCLM3 and normal liver THLE-2 cells (all from Mingzhoubio, Ningbo, China) were cultivated in a 5% CO2 incubator with dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) (Gibco, Carlsbad, California, USA), 50 μg gentamicin and 50 U/mL penicillin (HyClone Company, Logan, UT, USA). Cells in the logarithmic growth phase were taken for reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot detection of miR-130a and EGR1 expression.
The total RNA was extracted from tissues and cells by Trizol kit (Invitrogen). RNA concentration was determined by an ultraviolet spectrophotometer, and RNA was reversely transcribed into cDNA with reference to miScript Reverse Transcription Kit (Takara, Shiga, Japan). According to the instructions of SYBR Premix Ex Taq™ PCR Kit (Takara), the fluorescence quantitative PCR reaction was carried out on the fluorescence quantitative PCR instrument (Roche Diagnostics GmbH, Mannheim, Germany). U6 was the loading control of miR-130a, while GAPDH was that of EGR1. The primer sequences were compounded by Shanghai Genechem Co., Ltd. (Shanghai, China) (Table 3). The data were computed by $2^{-\Delta\Delta Ct}$ method.

**RT-qPCR**

Western blot analysis

Tissue and cell protein were extracted with a radio-immunoprecipitation assay lyisis buffer, and the protein concentration was detected by the bicinchoninic acid method. Upon sodium dodecyl sulfate polyacrylamide gel electrophoresis separation, the protein was transferred onto a polyvinylidene fluoride membrane by a water bath electroporator. The membrane was blocked with 5% skimmed milk, probed with primary antibody against EGR1 (1: 1000), and GAPDH (1: 1000, both from Abcam, MA, USA), and reprobed with secondary antibody labeled with horse-radish peroxidase (1: 10,000, Abcam). The image was exposed and scanned. Image J software was adopted for assessing gray value of the target band.

**Immunohistochemistry**

The paraffin sections of tumor tissues were hydrated with different concentrations of ethanol (100, 95, 85, 70%) and deionized water, then soaked in citric acid buffer (0.01 mol/L, pH 6.0), and heated at 95–100 °C. Then, the sections were added with 0.5% Triton × 100, stained with biotin-streptavidin HRP (ZSGB, China) and incubated with the corresponding...
antibody overnight. The brown stain on the membrane indicated a positive immunoreaction. The percentage of positively stained cells was calculated. The image was visualized using Nikon ECLIPSE Ti (Fukasawa, Japan) and analyzed with Nikon software.

**Fig. 4** Silencing EGR1 inhibits HCC progression. **A, B** EGR1 expression in HCC cells tested by RT-qPCR and western blot analysis after upregulating or downregulating EGR1; **C** OD value tested by MTT test after upregulating or downregulating EGR1; **D** Colony-forming ability of HCC cells tested by colony formation assay after upregulating or downregulating EGR1; **E** Migration and invasion of HCC cells tested by Transwell test after upregulating or downregulating EGR1 (scale bar = 50 μm); **F** Migration distance of HCC cells tested by scratch test after upregulating or downregulating EGR1 (scale bar = 200 μm); **G** Apoptosis of HCC cells tested by flow cytometry after upregulating or downregulating EGR1. N = 3. The data were expressed as mean±standard deviation and compared by one-way ANOVA. *p < 0.05 vs. the oe-NC group; ^p < 0.05 vs. the si-NC group.

The brown stain on the membrane indicated a positive immunoreaction. The percentage of positively stained cells was calculated. The image was visualized using Nikon ECLIPSE Ti (Fukasawa, Japan) and analyzed with Nikon software.

**Dual-luciferase reporter gene assay**
The target sites of EGR1 and miR-130a were determined by bioinformatics websites miRanda, starBase and DIANA. EGR1 3’ untranslated region (UTR)-wild-type (WT) and EGR1 3’UTR-mutant type (MUT) fragments were
Fig. 5 Elevating miR-130a enhances the inhibitory effects of DEX on HCC. 

A miR-130a expression tested by RT-qPCR after DEX treatment and upregulating miR-130a; 

B OD value tested by MTT test after DEX treatment and upregulating miR-130a; 

C Colony-forming ability of HCC cells tested by colony formation assay after DEX treatment and upregulating miR-130a; 

D Migration and invasion of HCC cells tested by Transwell test after DEX treatment and upregulating miR-130a (scale bar = 50 μm); 

E Migration distance of HCC cells tested by scratch test after DEX treatment and upregulating miR-130a (scale bar = 200 μm); 

F Apoptosis of HCC cells tested by flow cytometry after DEX treatment and upregulating miR-130a. N = 3. The data were expressed as mean±standard deviation and compared by one-way ANOVA. *p < 0.05 vs. the DEX + mimic NC group; †p < 0.05 vs. the DEX + inhibitor NC group.
cell viability was calculated. Dead cells were counted and recorded by a CountStar cell counter, and the blue staining solution (Sigma-Aldrich, CA, USA) was adopted for cell transfection.

miR-130a, si-EGR1, and the corresponding NCs were constructed by Ribobio Shanghai Sangon Biotechnology Co. Ltd. (Shanghai, China) while oe-EGR1, 130a mimic, inhibitor, and the corresponding NCs were compounded by Ribobio. miR-130a mimic, inhibitor NC, si-EGR1, si-NC, oe-EGR1 or oe-NC, respectively. MiR-130a was upregulated by transfection with miR-130a mimic, mimic NC, miR-130a inhibitor, miR-130a inhibitor NC, oe-EGR1, oe-NC, respectively. MiR-130a mimic, inhibitor, and the corresponding NCs were compound by Sangon with Not and Xho endonuclease cleavage sites at both ends, then recombined into the psi-CHECK2 polyclone sites. The WT and MUT sequences were identified. HCCLM3 cells were seeded into a 24-well plate. With 80% confluence, cells were transfected. The transfection reagent was arranged according to Lipofectamine™ 2000 specification (Invitrogen Inc., Carlsbad, CA, USA). The dual-luciferase reporter vectors (50 ng) and miR-130a mimic or mimic NC (50 nmol/L) were co-transfected into HCCLM3 cells. The luciferase activity was verified by Dual-luciferase Report Assay System (Promega, Madison, WI, USA) 48 h later.

Trypan blue staining
HCCLM3 cells which had been treated with 1, 10, 100 nmol/L DEX for 24 h were collected. HCCLM3 single-cell suspension (100 μL) and 100 μL trypan blue staining solution (Sigma–Aldrich, CA, USA) were reacted for 3 min. The dead cells were counted and recorded by a CountStar cell counter, and the cell viability was calculated.

Cell transfection
When the optimal concentration of DEX on cells was determined, HCCLM3 cells were treated with 10 nmol/L DEX for 24 h and transfected with miR-130a mimic, mimic NC, miR-130a inhibitor or inhibitor NC. At the same time, cells were also transfected with miR-130a mimic, mimic NC, miR-130a inhibitor, inhibitor NC, si-EGR1, si-NC, oe-EGR1 or oe-NC, respectively. MiR-130a mimic, inhibitor, and the corresponding NCs were compounded by Shanghai Sangon Biotechnology Co. Ltd. (Shanghai, China) while oe-EGR1, si-EGR1, and the corresponding NCs were constructed by Ribobio (Guangzhou, China). Lipofectamine 2000 reagent (Invitrogen Inc., Carlsbad, CA, USA) was adopted for cell transfection.

Transwell assay
HCCLM3 cells (1 × 10^5) were suspended in 200 μL serum-free DMEM and cultured on the upper layer of the transwell chamber (without matrigel, BD Biosciences, NJ, USA) with 40 μL/well. The lower layer was added with 500 μL DMEM/10% FBS/50 μg fibronectin. Cells were dyed with 0.1% crystal violet staining solution. Five fields of view were randomly selected to count cells.

Transwell invasion experiment: matrigel (500 μL, BD Biosciences) was appended in the upper layer in advance and then added with cell suspension. The rest of the steps were the same as the migration experiment.

Scratch test
HCCLM3 cells (5 × 10^5 cells) were cultured in a 35 mm dish, with two parallel wells in each group. After the cells completely adhered to the wall, a 1 mL pipette tip was utilized to scratch the cell monolayer (the scratch was smooth, complete and continuous under the microscope). Cells falling off were washed by PBS, and observed under the light microscope. The cell growth at the scratch was observed and recorded, and the migration distance was recorded after continuing to be cultured for 1 day.

Flow cytometry
HCCLM3 cells (1 × 10^6 cells) were fixed by pre-cooled 70% ethanol overnight. Rinsed with cold PBS, cells were combined with 100 μL 1 × binding buffer, added with 5 μL Annexin V-fluorescein isothiocyanate and 5 μL PI for 10 min. Cell apoptosis was tested by a flow cytometer within 1 h.

Statistical analysis
All data analysis was conducted using SPSS 19.0 software (IBM, NY, USA). The experimental results were showed as the mean ± standard deviation. The t test was performed for comparisons between two groups and one-way analysis of variance (ANOVA) was used for comparisons among multiple groups, followed by Tukey’s post-hoc test. Statistical significance was set at p < 0.05.

DATA AVAILABILITY
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

REFERENCES
1. Coskun M. Hepatocellular carcinoma in the cirrhotic liver: evaluation using computed tomography and magnetic resonance imaging. Exp Clin Transpl. 2017;15(Suppl 2):36–44.
2. Huang D, Wei Y, Zhu J, Wang F. Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCD4 expression by sponging miR-195-5p in hepatocellular carcinoma. Gene. 2019;714:143994.
3. Yin L, He N, Chen C, Zhang N, Lin Y, Xia Q. Identification of novel blood-based HCC-specific diagnostic biomarkers for human hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):1908–16.
4. Elalfy H, Beheer T, El-Makroud MA, Farid K, Elegezy M, El Nakib AM, et al. Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. Br J Biomed Sci. 2018;75(4):187–91.
28. Xia M, Tong JH, Zhou ZQ, Duan ML, Xu JG, Zeng HJ, et al. Tramadol inhibits cell death Discovery (2022) 8:31.

29. Zheng L, Jia R, Zhao J. Desmethylmetdorfin regulates proliferation, apoptosis, migration, and invasion in ovarian cancer cells via MIR-155-HIF-1alpha axis. Med Sci Monit. 2019;25:10164–72.

30. Wang X, Xu Y, Chen X, Xiao J. Desmethylmetdorfin inhibits osteosarcoma cell proliferation and migration, and promotes apoptosis by regulating miR-520a-3p. Oncol Rep. 2018;26(3):495–502.

31. Sun Y; Li L; Wu J; Gong B; Liu H. Germacrone cooperates with desmethylmetdorfin to alleviate high-fat diet-induced type 2 diabetes mellitus via upregulating AMPKalpha1 expression. Exp Ther Med. 2019;18(5):3514–24.

32. Yang C, He L, Wang C, Huang Y, Wang A, Li X, et al. Desmethylmetdorfin alleviated lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. Int Immunopharmacol. 2019;72:367–73.

33. Lu M, Zeng H, He Y, Zhong J, Tan G. Desmethylmetdorfin promotes liver regeneration in mice after 70% partial hepatectomy by suppressing NLRP3 inflammasome not TLR4/NFkappaB. Int Immunopharmacol. 2018;54:46–51.

34. Lavon H, Matzner P, Benbenishty A, Sorksi L, Rossene E, Haldar R, et al. Desmethylmetdorfin promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120(1):188–96.

35. Su X, Fan Y, Yang L, Huang J, Qiao F, Fang Y, et al. Desmethylmetdorfin expands monocytic myeloid-derived suppressor cells and promotes tumour metastasis after lung cancer surgery. J Transl Med. 2018;16(1):347.

36. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.

37. Liu HL, Bao HG, Zheng CL, Ceng T, Bai MH. MiR-130a regulating the biological function of colon cancer targeted by inhibition of PTEN. Eur Rev Med Pharmacol Sci. 2020;24(12):3076–86.

38. Zhou SY, Chen W, Yang SJ, Li J, Zhang JY, Zhang HD, et al. Circular RNA circVAPA regulates breast cancer cell migration and invasion via sponging miR-130a-5p. Epigenomics. 2020;12(4):303–17.

39. Sun Z, Gao S, Xuan L, Liu X. Long non-coding RNA FEZF1-A51 induced progression of ovarian cancer via regulating miR-130a-5p/SDX4 axis. J Cell Mol Med. 2020;24(2):2475–85.

40. Liu Y, Li Y, Wang R, Qin S, Liu J, Su F, et al. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in genticablate resistant hepatoma cells. J Exp Clin Cancer Res. 2016;35:344.

41. Li B, Huang P, Qin J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31(10):230.

42. Shen J, Siegel AB, Remotti H, Wang Q, Santella RM. Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies. Hepatoma Res. 2016;2:151–62.

43. Li S, Duan X, Li Y, Liu B, McGillivray I, Chen L. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat. 2014;21(2):121–8.

44. Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cells. Biochem Biophys Res Commun. 2012;422(5):468–72.

45. Guo Y, Lu G, Mao H, Zhou S, Tong X, Wu J, et al. miR-133b suppresses invasion and migration of gastric Cancer cells via the COL1A1/TGF-beta axis. Onco Targets Ther. 2020;13:7985–95.

46. Ozen E, Guzziuel A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS ONE. 2012;7(8):e42717.

47. Bi JG, Zheng JF, Li Q, Bao SY, Xu X, Wu P, et al. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting TGF-beta/Smad pathway in hepatocellular carcinoma. Onco Targets Ther. 2019;12:1705–16.

48. Peng WX, Xiong EM, Ge L, Wang J, Sun YY, Zou Y. Knockdown of LncRNA H19 relieves LPS-induced damage by modulating miR-130a in osteoarthritis. Yonsei Med J. 2019;60(4):381–8.

49. Li L, Chen J, Ge C, Zhao F, Chen T, Tian H, et al. CD24 isoform a promotes cell migration, proliferation and invasion and is downregulated by EGR1 in hepatocellular carcinoma. Exp Cell Res. 2016;340(1):62–70.

50. Liver H, Bao HG, Zheng CL, et al. Beta-catenin signaling regulates AKT/beta-catenin activation in hepatocellular carcinoma. Cancer Biol Ther. 2006;5(7):993–1003.

51. Ding H, Liu J, Zou R, Cheng P, Su Y, et al. Long non-coding RNA TPTPTE1 inhibits hepatocellular carcinoma progression by targeting EGFR and inhibiting Egr1/TGF-beta/Smad pathway in hepatocellular carcinoma. Int J Biochem Cell Biol. 2019;106:107–16.

52. Bi JG, Zheng JF, Li Q, Bao SY, Xu X, Wu P, et al. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-beta/Smad pathway in hepatocellular carcinoma. Exp Cell Res. 2016;340(1):62–70.

53. Peng WX, Xiong EM, Ge L, Wang J, Sun YY, Zou Y. Knockdown of LncRNA H19 relieves LPS-induced damage by modulating miR-130a in osteoarthritis. Yonsei Med J. 2019;60(4):381–8.

54. Liver H, Bao HG, Zheng CL, et al. Beta-catenin signaling regulates AKT/beta-catenin activation in hepatocellular carcinoma. Cancer Biol Ther. 2006;5(7):993–1003.
FUNDING
The study is funded by National Natural Science Foundation of China (81702824); National Natural Science Foundation of China (81901842); China Primary Health Care Foundation (YLGX-WS-2020003).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00805-5.

Correspondence and requests for materials should be addressed to Xinlin Yin, Kuan Hu or Wen Ouyang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022